PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours.

Abstract

PATRIOT is a phase I study of the ATR inhibitor, AZD6738, as monotherapy, and in combination with palliative radiotherapy. Here, we describe the protocol for this study, which opened in 2014 and is currently recruiting and comprises dose escalation of both drug and radiotherapy, and expansion cohorts.

• Authors: M T Dillon, Z Boylan, D Smith, J Guevara, K Mohammed, C Peckitt, M Saunders, U Banerji, G Clack, S A Smith, J F Spicer, M D Forster, K J Harrington
• Journal: Clinical and translational radiation oncology (Clin Transl Radiat Oncol) Vol. 12 Pg. 16-20 (Aug 2018) ISSN: 2405-6308 [Electronic] Ireland
• PMID: 30073210 (Publication Type: Journal Article)